Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Table 1 Patient characteristics and response to therapy

Clinical features	AOSD course	Therapy before CAN (mg)	Lab tests before CAN	Therapy after CAN (mg)	Lab tests after CAN	Response to CAN	Modified Pouchot score before CAN	Modified Pouchot score after CAN	Side effect
A, M, R, F, S	SD	PDN (15) MTX (20)	ESR 40 CRP 31.5 Ferritin 715	MTX (20)	ESR 12 CRP 4.2 Ferritin 140	Complete	7	1	None
A, M, R, F, HSM	SD	PDN (25) MTX (20)	ESR 45 CRP 8.2 Ferritin 880	PDN (5) MTX (15)	ESR 7 CRP 3.7 Ferritin 135	Complete	6	2	None
A, M, F, L, S	SD	PDN (10) MTX (10)	ESR 32 CRP 31.1 Ferritin 1324	–	ESR 12 CRP 5.7 Ferritin 98	Complete	5	1	None
A, M, F, P, R	SD	PDN (25) MTX (20)	ESR 57 CRP 17.4 Ferritin 1025	PDN (2.5) MTX (20)	ESR 9 CRP 2.1 Ferritin 119	Complete	6	1	None

AOSD duration indicates duration of disease before initiation of canakinumab (CAN). Disease manifestations: A arthritis; M myalgia; F fever; R rash; P pharyngitis; S serositis; L lymphadenopathies; HSM hepatosplenomegaly. Therapy before CAN indicates the treatment regimen that was being administered at the time of CAN initiation; therapy after CAN indicates the maintenance therapy that was being administered at the last follow-up visit. PDN prednisone; MTX methotrexate; SD systemic disease; ESR erythrocyte sedimentation rate (mm/1 h, normal values < 30 mm/1 h); CRP C-reactive protein (mg/L, < 6 mg/L); ferritin (ng/mL, 15–150 ng/mL). The modified Pouchot score for measuring AOSD disease activity evaluates clinical and laboratory manifestations and ranges from 0 to 12, with scores above 4 indicating active disease

ISSN: 1478-6362